

## Supplementary Digital Content 1. Concomitant Medications at Study Entry Through Blinded Phase

Concomitant Medications		Gabapentin (mg/day)							
		0 (placebo) Subjects (N = 44)		1 Subjects (N = 42)		6 Subjects (N = 41)		30 Subjects (N = 43)	
Category	Medication	n	(%)	n	(%)	n	(%)	n	(%)
Anti-convulsants	Gabapentin *	9	20.5%	9	21.4%	6	14.6%	7	16.3%
	Other anticonvulsants	10	22.7%	8	19.0%	6	14.6%	8	18.6%
	Pregabalin *	6	13.6%	6	14.3%	3	7.3%	6	14.0%
Narcotic Analgesics	Code undeterminable	1	2.3%	0	0.0%	0	0.0%	0	0.0%
	Codeine	2	4.5%	0	0.0%	1	2.4%	1	2.3%
	Fentanyl	33	75.0%	31	73.8%	33	80.5%	34	79.1%
	Hydrocodone	25	56.8%	18	42.9%	19	46.3%	18	41.9%
	Hydromorphone	11	25.0%	12	28.6%	17	41.5%	20	46.5%
	Meperidine	8	18.2%	8	19.0%	6	14.6%	7	16.3%
	Methadone	7	15.9%	7	16.7%	9	22.0%	6	14.0%
	Morphine	20	45.5%	17	40.5%	18	43.9%	19	44.2%
	Oxycodone	21	47.7%	24	57.1%	26	63.4%	28	65.1%
	Oxymorphone	3	6.8%	2	4.8%	3	7.3%	1	2.3%
	Propoxyphene	3	6.8%	1	2.4%	2	4.9%	1	2.3%
Psychotherapeutic Agents	Atypical antipsychotic	7	15.9%	4	9.5%	10	24.4%	10	23.3%
	Code undeterminable	0	0.0%	0	0.0%	1	2.4%	0	0.0%
	Miscellaneous antidepressant	1	2.3%	1	2.4%	1	2.4%	1	2.3%
	Norepinephrine-dopamine reuptake inhibitor	0	0.0%	0	0.0%	0	0.0%	1	2.3%
	Phenothiazine antipsychotic	0	0.0%	2	4.8%	2	4.9%	2	4.7%
	SSRI	8	18.2%	9	21.4%	10	24.4%	10	23.3%
	Serotonin-norepinephrine reuptake inhibitor	22	50.0%	16	38.1%	12	29.3%	18	41.9%
	Tetracyclic antidepressant	7	15.9%	6	14.3%	11	26.8%	11	25.6%
	Tricyclic antidepressant	8	18.2%	9	21.4%	6	14.6%	5	11.6%

\*Oral gabapentin and pregabalin were discontinued before implantation (before the blinded phase).

SSRI = selective serotonin reuptake inhibitor.